The deleterious effects of VEGF222/NF in immunodeficient mice and zebrafish prompted us to analyse the prognostic significance of its plasmatic levels compared with plasmatic VEGF levels in a cohort of 47 metastatic (M1) ccRCC patients treated with sunitinib and in a cohort of 30 patients treated with bevacizumab plus interferon alpha or temsirolimus [49]. This evidence concerns the gene VEGFA and nonpapillary renal cell carcinoma.